Standout Papers

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cogn... 2006 2026 2012 2019 1.2k
  1. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study (2006)
    Oskar Hansson, Henrik Zetterberg et al. The Lancet Neurology
  2. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia (2020)
    Shorena Janelidze, Niklas Mattsson et al. Nature Medicine
  3. Biomarkers for neurodegenerative diseases (2021)
    Oskar Hansson Nature Medicine
  4. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup (2024)
    Clifford R. Jack, J. Scott Andrews et al. Alzheimer s & Dementia
  5. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017)
    Sebastian Palmqvist, Michael Schöll et al. Nature Communications
  6. CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts (2018)
    Oskar Hansson, John Seibyl et al. Alzheimer s & Dementia
  7. Plasma β-amyloid in Alzheimer’s disease and vascular disease (2016)
    Shorena Janelidze, Erik Stomrud et al. Scientific Reports
  8. CSF and blood biomarkers for Parkinson's disease (2019)
    Lucilla Parnetti, Lorenzo Gaetani et al. The Lancet Neurology
  9. Four distinct trajectories of tau deposition identified in Alzheimer’s disease (2021)
    Jacob W. Vogel, Alexandra L. Young et al. Nature Medicine
  10. Plasma tau in Alzheimer disease (2016)
    Niklas Mattsson, Henrik Zetterberg et al. Neurology
  11. Blood-based NfL (2017)
    Oskar Hansson, Shorena Janelidze et al. Neurology
  12. Amyloid biomarkers in Alzheimer's disease (2015)
    Kaj Blennow, Niklas Mattsson et al. Trends in Pharmacological Sciences
  13. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease (2019)
    Oskar Hansson, Sylvain Lehmann et al. Alzheimer s Research & Therapy
  14. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease (2016)
    Shorena Janelidze, Henrik Zetterberg et al. Annals of Clinical and Translational Neurology
  15. Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures (2021)
    Sebastian Palmqvist, Pontus Tideman et al. Nature Medicine
  16. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease (2021)
    Joana B. Pereira, Shorena Janelidze et al. Brain
  17. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019)
    Sebastian Palmqvist, Shorena Janelidze et al. JAMA Neurology
  18. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease (2022)
    Oskar Hansson, Rebecca M. Edelmayer et al. Alzheimer s & Dementia
  19. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease (2020)
    Shorena Janelidze, Erik Stomrud et al. Nature Communications
  20. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials (2022)
    Rik Ossenkoppele, Rik van der Kant et al. The Lancet Neurology
  21. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease (2021)
    Shorena Janelidze, Charlotte E. Teunissen et al. JAMA Neurology
  22. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease (2022)
    Shorena Janelidze, Divya Bali et al. Brain
  23. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease (2019)
    Sebastian Palmqvist, Philip S. Insel et al. EMBO Molecular Medicine
  24. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease (2020)
    Shorena Janelidze, David Berron et al. JAMA Neurology
  25. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease (2020)
    Niklas Mattsson, Emelie Andersson et al. Science Advances
  26. Blood‐based biomarkers for Alzheimer's disease (2021)
    Antoine Leuzy, Niklas Mattsson et al. EMBO Molecular Medicine
  27. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment (2021)
    Claudia Cicognola, Shorena Janelidze et al. Alzheimer s Research & Therapy
  28. Blood biomarkers for Alzheimer’s disease in clinical practice and trials (2023)
    Oskar Hansson, Kaj Blennow et al. Nature Aging
  29. Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations (2021)
    Nicholas Cullen, Antoine Leuzy et al. Nature Communications
  30. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers (2023)
    Niklas Mattsson, Gemma Salvadó et al. JAMA Neurology
  31. Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance (2022)
    Alexa Pichet Binette, Shorena Janelidze et al. Alzheimer s & Dementia
  32. A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases (2023)
    Wagner S. Brum, Nicholas Cullen et al. Nature Aging
  33. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads (2023)
    Gemma Salvadó, Rik Ossenkoppele et al. EMBO Molecular Medicine
  34. Clinical effects of Lewy body pathology in cognitively impaired individuals (2023)
    Corinne Quadalti, Sebastian Palmqvist et al. Nature Medicine
  35. Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios (2023)
    Shorena Janelidze, Nicolas R. Barthélemy et al. JAMA Neurology
  36. Cognitive effects of Lewy body pathology in clinically unimpaired individuals (2023)
    Sebastian Palmqvist, Marcello Rossi et al. Nature Medicine
  37. Disease staging of Alzheimer’s disease using a CSF-based biomarker model (2024)
    Gemma Salvadó, Kanta Horie et al. Nature Aging
  38. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort (2024)
    Federica Ribaldi, Aurélien Lathuilière et al. Journal of Neurology
  39. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup (2025)
    Gil D. Rabinovici, David S. Knopman et al. Alzheimer s & Dementia
  40. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease (2025)
    Jeffrey L. Cummings, Alireza Atri et al. Alzheimer s Research & Therapy
  41. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease (2025)
    Kanta Horie, Gemma Salvadó et al. Nature Medicine

Immediate Impact

5 by Nobel laureates 12 from Science/Nature 153 standout
Sub-graph 1 of 18

Citing Papers

Biomarker Changes during 20 Years Preceding Alzheimer’s Disease
2024 Standout
Emerging diagnostics and therapeutics for Alzheimer disease
2023 Standout
63 intermediate papers

Works of Oskar Hansson being referenced

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
2022 Standout
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
2021 Standout
and 91 more

Author Peers

Author Last Decade Papers Cites
Oskar Hansson 20696 15250 6465 8714 781 38.1k
Julie A. Schneider 20574 17036 7800 8136 515 45.5k
Richard Mayeux 20883 19443 7316 8065 514 51.2k
Hilkka Soininen 16451 15704 3849 6315 672 39.3k
Harald Hampel 17391 13531 3116 7438 489 34.0k
Carol Brayne 13130 19317 7977 4191 723 53.7k
Monique M.B. Breteler 15321 15543 13522 6780 478 64.6k
Leslie M. Shaw 16704 15815 3593 5890 359 32.9k
Serge Gauthier 11678 15085 4541 5057 560 34.5k
Wiesje M. van der Flier 14298 16264 5055 4193 777 33.3k
Martin N. Rossor 23202 23205 9392 10164 474 53.7k

All Works

Loading papers...

Rankless by CCL
2026